Rna
Early declines in serum hepatitis B RNA levels may ‘serve as independent predictors’ of HCC
Declines in serum hepatitis B virus RNA at the first and second year of treatment with nucleos(t)ide analogues correlated with risk for hepatocellular carcinoma and may serve as independent predictors of cancer development.
FDA clears first ‘rapid diagnostic’ hepatitis C RNA test for point-of-care settings
The FDA granted marketing authorization for Cepheid’s Xpert HCV test and GeneXpert Xpress System, the first rapid test for hepatitis C virus intended for use in point-of-care settings.
RNA interference silences RAGE with no detrimental effect on lungs in patients with asthma
SAN DIEGO — Study participants tolerated an inhaled therapeutic that silences the expression of a receptor for advanced glycation end-products in the lungs, according to a poster at the American Thoracic Society International Conference.
VIDEO: Small interfering RNA holds promise for cardiovascular care
BOSTON —Small interfering RNA technology has the potential to become a novel treatment approach in cardiovascular medicine, according to Clyde W. Yancy, MD, MSc, MACP, MACC, FAHA, FHFSA.
Collaboration to advance small activating RNA therapeutics for central nervous system
A London-based biotech firm has announced a collaboration and licensing agreement with a Japanese pharmaceutical firm for discovery, development and commercialization of small activating RNA therapeutics for rare neurodegenerative diseases.
Bulevirtide induces a virologic, biochemical response in chronic hepatitis D
Bulevirtide was safe and increased the proportion of patients with undetectable hepatitis D virus RNA among those in both the 2 mg and 10 mg dosage groups, according to data published in The New England Journal of Medicine.
New approach needed to manage adults with colorectal cancer, fatty liver
Proteins and genetic material secreted by fatty liver cells stimulate the spread of colorectal cancer to the liver, study results published in Cell Metabolism showed.
FDA grants orphan drug designation to RNA therapy for Charcot-Marie-Tooth disease type 1A
The FDA has granted orphan drug designation to DTx-1252, an investigational small interfering RNA therapeutic to treat Charcot-Marie-Tooth disease type 1A.
RNA sampling via tape strips may rule out melanoma in suspicious lesions
Obtaining RNA samples from suspicious lesions via tape stripping was found to be a valid technique for detecting cutaneous malignant melanoma, according to a study.
FDA grants orphan drug designation for rare pediatric skeletal disease therapy
The FDA granted orphan drug designation and rare pediatric disease designation for a therapy to treat a rare pediatric skeletal disorder, according to an industry press release.